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ABSTRACT 
Cardiovascular diseases (CVD) are of prime importance among lifestyle disease and dyslipidemia is an 
independent and modifiable risk factor for CVD, together with smoking and sedentary habits, fatty diets and 
stressful life situations. Dyslipidemia can be included under the term Medovikaras in Ayurveda. . A 
combination of Erandapathrakshara (Ricinus communis Linn) and Hingu (Ferula narthex Linn) is mentioned in 
Bhavaprakasa for curing Medovriddhi. At present era, many modern medications are available for curing the 
elevated lipid levels. But they cause many side effects which are extremely hazardous to human health. So a 
clinical study is selected with an interest to revalidate the ancient scientific knowledge. Genuine samples of 
both Eranda (Ricinus communis Linn) and Hingu (Ferula narthex Linn) were collected. Thekshara of 
Erandapathra and powder of purified Hingu were given to the patient with Mandam (supernatant liquid 
portion of rice soup) as Anupaana for a period of 1 month. Patients of both sexes in the age group of 30-60 
years with serum LDL above 130mg/dl, non HDL-C above 139mg/dl from OPD. The statistical analysis of 
changes in Lipid profile values before treatment, after treatment, and after follow up are the assessment 
criteria. Trial drugs were found to be effective in reducing T. Cholesterol, LDL, triglycerides and Non-HDL-c 
but not effective in reducing VLDL and increasing HDL and no side effects were observed during study period. 
From the present study we can conclude that the trial drugs were effective and can be used safely in clinical 
practice in future.  
KEYWORDS: Dyslipidemia, Ricinus communis Linn, Ferula narthex. Linn, LDL, Non-HDL-C, T. cholesterol, 
VLDL, Triglycerides, HDL. 
INTRODUCTION
Ayurveda offers a strong framework for multi-
modal preventive medicine. It is also patient friendly, non-
pharma compliment for managing chronic diseases 
refractory to allopathic therapies. Traditional medicine 
uses different plant parts and extracts derived from 
medicinal plants. High cost of new drugs, increased side 
effects of modern medicines, microbial resistance and 
emerging diseases are some of the reasons for more 
interest from public in using complementary and 
alternative medicine nowadays. But most of the 
researchers consider Ayurveda as pseudoscientific as it 
lack scientific evidence in treatment. So it is our duty to 
conduct more researches in the field of Ayurveda and 
ignite this as evidence based science.  
A combination of Erandapathrakshara and Hingu 
is mentioned in Bhavaprakasa for curing Medovriddhi[1]. 
Medovriddhi may be correlated to the condition 
dyslipidemia. Dyslipidemia is the elevation of plasma 
cholesterol, triglycerides, or both or a low level of High 
density lipoprotein[2]. This may contribute to the formation 
of atherosclerosis. The incidence of dyslipidemia is 
increasing in many developing countries due to 
westernization of diets and other lifestyle changes. 
Correction of dyslipidemia can reduce the risk of heart 
disease by 30% over a 5 year period[3]. NCEP (National 
Cholesterol Education Programme) guidelines of United 
States recommend cholesterol levels less than 200mg/dl[4]. 
The values exceeding 240mg/dl are considered as high 
risk factor. The prevalence of dyslipidemia is very high in 
India which calls for urgent lifestyle intervention 
strategies to prevent and manage this important 
cardiovascular risk factor.  
Updated 2016 guidelines deal with the 
management of dyslipidemia as an essential and integral 
part of cardiovascular disease prevention[5]. The 
conventional cholesterol lowering drugs like Statins, Bile 
acid sequestrants, Ezetimibe and Fibrates causes many 
side effects including elevation of liver enzymes, nausea, 
constipation, hyperurecemia etc[6]. So there is a need to 
invent a new, cost effective and safe medicine to cure 
dyslipidemia.  
Medicinal plants have been identified and used 
from prehistoric times. Plants make many chemical 
compounds for biological functions, including defence 
against insects, fungi and herbivorous mammals. Over 
12000 active compounds are known to science. So more 
works should be conducted in these herbs to revalidate the 
ancient scientific knowledge. As evidence based medicine 
is the need of the hour, this study is an attempt to test 
clinically the efficacy of Erandapathrakshara along with 
Hingu in dyslipidemia.  
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AIMS AND OBJECTIVES  
To evaluate clinically the effect of 
Erandapathrakshara along with Hingu in dyslipidemia by 
orally administering the drug for 30 days and to assess the 
lipid profile values before treatment (BT), after treatment 
(AT) and after 30 days follow up.  
MATERIALS AND METHODS 
Collection of the drug 
The study drug Eranda (Ricinus communis Linn) 
(20kg) was collected from its natural habitat, 
Karunagappally, Kollam district, Kerala. 500g of Medicinal 
Hingu (Ferula narthex Linn) was purchased for the study.  
Preparation of drug 
The fresh plants were collected, leaves were 
separated along with petiole, washed well and shade dried. 
The Kshara was prepared from it according to the method 
mentioned in AFI.  
Drug is cut into small pieces and dried well. Pieces 
are put in earthen pot and burnt to ash. The ash is allowed 
to cool. Water is added in the ratio 6:1 and mixed well. 
Then strained through a piece of cloth. This process of 
straining done 2-3 times till a clear liquid is obtained. This 
liquid is then put in an iron/earthen vessel and heated 
over a moderate fire till the water evaporates leaving a 
solid salty white substance which is collected known as 
Kshara. (AFI)[7] 
500 g of Kshara is prepared from 20kg of leaves; 
250 mg of Kshara was measured, and packed tightly in 
butter papers.  
 Medicinal Hingu (Ferula narthex Linn.) was 
purchased and identity tests were done in the lab for 
checking its genuineness. Hingu was purified by frying 
with Ghritha until it becomes dry and hard. Then it is 
powdered well for internal use and 125mg is packed air 
tightly in butter papers.  
Inclusion Criteria 
1. Patients of both sexes in age group of 30-60 years.. 
2. LDL level above 130mg/dl, non HDL-C level above 139 
mg/dl. 
Exclusion Criteria 
1. Pregnant and lactating woman 
2. Known cases of medication for coronary artery disease, 
cerebrovascular accidents, any type of malignancy, 
renal and hepatic disorders.  
3. Those who are contraindicated for Kshara. 
Sample Size 
Total 33 patients were selected from the 
outpatient department, Dravyagunavijnana, Govt. 
Ayurveda college hospital, Trivandrum, having 
dyslipidemia confirmed by assessing lipid profile.  
Dose 
Dose of Kshara (R. T)-250 mg-1g.[8] 
Dose of Hingu (API) 10-125-500mg of drug.[9] 
 An intermediate values of the above mentioned 
weights of Kshara and Hingu are opted as dosage for pilot 
study. Thus, 250mg of Kshara mixed with 125mg of 
purified Hingu powder (in the ratio 2:1) and a total 375mg 
medicine will be given with Mandam twice daily.  
Duration 
1 month, and follow up for 1 month 
Route of administration 
Oral 
Collection of data 
Data was collected before the study, after the 
study and after 30 days follow up by interview and 
laboratory investigations according to the structured case 
proforma, a model of which is given in the appendix. The 
data includes personal data such as name, religion, 
occupation etc. , data related to disease such as chief 
complaints and its duration, history of present and past 
illness, menstrual history, history of obstetrics etc. General 
and systemic examinations were conducted.  
Investigations 
Dyslipidemia was assessed by checking serum 
lipid profile and non-HDL cholesterol of the patient before 
and after the study and after follow up. Lipid profile 
includes Total cholesterol, HDL, LDL, VLDL and 
Triglycerides.  
Assessment Criteria 
Laboratory findings- BT, AT and after follow up. 
Total cholesterol, HDL, LDL, VLDL, Triglycerides, non- 
HDL-C. 
Ethical consideration 
Every patient was selected in the study after 
obtaining an informed consent from them. Before starting 
the study, No Objection Certificate was obtained from 
Institutional Ethical Committee (IEC) with ref. no IEC 
135/28. 4. 2015.  
Observation, Analysis and Results 
Majority of the patients were in between age 
group 51-60 years. In this study 30% of patients were 
male and 70% were female. 94% belonged to middle class, 
6% were poor, and 0% was rich. 45% were residing in 
rural area and 55% were residing in urban area. 6% were 
vegetarians and 94% were taking both vegetarian and 
non-vegetarian food. No patients had poor appetite, 97% 
had moderate and 3% had increased appetite. 6% had no 
exercise, 79% had mild exercise and 21% had moderate 
exercise.  
Effect of Treatment on Lipid Profile 
The average Lipid profile values before treatment, 
after treatment and after follow up are given below in the 
table.  
Table 1: Lipid Profile Values 
Lipid profile values BT AT AF 
Serum cholesterol 251. 27 241. 85 243. 09 
LDL 181. 39 171. 76 172. 64 
VLDL 22. 82 21. 24 21. 85 
Triglycerides 117. 45 105. 82 107. 27 
HDL 47. 12 48. 52 48. 09 
Non-HDL c 204. 09 193. 33 194. 91 
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Statistical Analysis 
The collected data were subjected to statistical 
analysis using SPSS v. 16 for WINDOWS. For categorical 
variables frequencies and percentages were used as 
summary measures. For continuous variables, mean and 
standard deviations were used as summary measures. For 
all continuous variables, before-after treatment effect was 
assessed using paired sample t test. Hence for testing the 
effectiveness of treatment, statistical significance of 
before-after treatment effects was carried out using paired 
t test.  
Table 2: Effectiveness of treatment on T. cholesterol 
 
N 
Total cholesterol (mg/dL)  
Effect 
Paired Differences 
% of change 
Paired t test 
Mean Sd Mean Sd t  P 
BT 33 251. 27 24. 67 BT-AT 9. 42 18. 03 -3. 75 3. 002 . 005 
AT 33 241. 85 25. 67 AT-AF -1. 24 5. 15 0. 51 1. 385 . 176 
AF 33 243. 09 26. 66 BT-AF 8. 18 19. 31 -3. 26 2. 434 . 021 
The paired t test showed that the decrease in cholesterol after treatment is statistically significant (t=3. 002, p<0. 
05) and there is significant effect in reducing cholesterol after follow up also (t=2. 434, p<0. 05). But there is no significant 
effect from after treatment to after follow up (t=1. 385, p>0. 05).  
Table 3:Effectiveness of treatment on LDL 
 
N 
LDL (mg/dL)  
Effect 
Paired Differences 
% of change 
Paired t test 
Mean sd Mean Sd t P 
BT 33 181. 39 27. 15 BT-AT 9. 64 20. 08 -5. 31 2. 757 . 010 
AT 33 171. 76 23. 87 AT-AF -0. 88 3. 83 0. 51 -1. 318 . 197 
AF 33 172. 64 22. 89 BT-AF 8. 76 17. 89 -4. 83 2. 812 . 008 
 The paired t test showed that the decrease in LDL after treatment is statistically significant (t=2. 757, p<0. 05) and 
there is significant effect in reducing cholesterol after follow up also (t=2. 812, p<0. 05). But there is no significant effect 
from after treatment to after follow up (t=1. 318, p>0. 05).  
Table 4: Effectiveness of treatment on VLDL 
 
N 
VLDL (mg/dL)  
Effect 
Paired Differences 
% of change 
Paired t test 
Mean sd Mean sd T P 
BT 33 22. 82 8. 67 BT-AT 1. 58 6. 35 -6. 91 1. 425 . 164 
AT 33 21. 24 6. 11 AT-AF -0. 61 1. 80 2. 85 1. 932 . 062 
AF 33 21. 85 6. 37 BT-AF 0. 97 5. 90 -4. 25 . 945 . 352 
 The paired t test showed that there is no significant effect in reducing VLDL level after treatment (t=1. 425, p>0. 
05) andafter follow up (t=0. 945, p>0. 05). There is no significant effect from after treatment to after follow up also (t=1. 
932, p>0. 05).  
Table 5:Effectiveness of treatment on Triglycerides 
 
N 
Triglycerides (mg/dL)  
Effect 
Paired Differences % of 
change 
Paired t test 
Mean sd Mean Sd T P 
BT 33 117. 45 42. 70 BT-AT 11. 64 29. 77 -9. 91 2. 245 . 032 
AT 33 105. 82 29. 36 AT-AF -1. 45 2. 87 1. 37 2. 908 . 007 
AF 33 107. 27 29. 71 BT-AF 10. 18 28. 03 -8. 67 2. 087 . 045 
 The decrease in Triglycerides after treatment is statistically significant (t=2. 245, p<0. 05)and there is significant 
effect in reducing Triglycerides after follow up also (t=2. 087, p<0. 05). There is a significant effect from after treatment to 
after follow up also (t=2. 908, p<0. 05).  
Table 6: Effectiveness of treatment on HDL 
 
N 
HDL (mg/dL)  
Effect 
Paired Differences % of 
change 
Paired t test 
Mean sd Mean Sd T P 
BT 33 47. 12 5. 82 BT-AT -1. 39 6. 45 2. 96 1. 242 . 223 
AT 33 48. 52 5. 24 AT-AF 0. 42 1. 95 -0. 87 1. 248 . 221 
AF 33 48. 09 4. 73 BT-AF -0. 97 5. 77 2. 06 -. 965 . 342 
 The paired t test showed that the increase in HDL level after treatment is statistically not significant (t=1. 242, 
p>0. 05) andthere is no significant effect in increasing HDL after follow up (t=1. 248, p>0. 05). There is no significant effect 
from after treatment to after follow up also (t=. 965, p>0. 05).  
Table 7: Effectiveness of treatment on Non HDL-C 
 
N 
Non-HDLC (mg/dL)  
Effect 
Paired Differences 
% of change 
Paired t test 
Mean sd Mean sd t P 
BT 33 204. 09 24. 51 BT-AT 10. 76 18. 68 -5. 27 3. 309 . 002 
AT 33 193. 33 24. 02 AT-AF -1. 58 6. 28 0. 82 -1. 443 . 159 
AF 33 194. 91 25. 31 BT-AF 9. 18 19. 67 -4. 50 2. 681 . 011 
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 There is a significant effect in reducing Non HDL-C level after treatment (t=3. 309, p<0. 05) and after follow up 
(t=2. 681, p<0. 05). But there is no significant effect from after treatment to after follow up (t=1. 443, p>0. 05).  
DISCUSSION 
Dyslipidemia can be correlated with Medovriddhi 
or Medovikara described in Ayurvedic classics. Many signs 
and symptoms mentioned by the increase of Medodhathu 
in body. Quantitative increase in various forms of lipids 
may be correlated with these signs and symptoms of 
Medovriddhi.[10] It can also be comparable with the 
condition of Athisthoulya mentioned in Samhithas.[11] A 
combination of Erandapathrakshara and Hingu is 
mentioned in Bhavaprakasa for curing Medovriddhi.[1] So a 
clinical study was conducted to assess the effect of this 
combination in Medovriddhi by assessing the lipid profile 
values.  
By analyzing sociodemographic data, 45% 
patients were in age group 51-60. This may be due to 
unsatisfactory food habits and degenerative changes of 
body cells. It reveals 70% patients were females which 
substantiates dyslipidemia is more prevalent among 
females. Majority of the patients are from middle class 
families (94%), indicates that it is a serious issue which 
affect majority of the public. 55% of patients from urban 
area which indicates that the disease is more prevalent in 
them due to taking fast food, junk food etc and may be due 
to polluted atmosphere. 
By analyzing statistical data, it can be stated that 
the study drug is effective in reducing TC, LDL, Non HDL-C 
and triglycerides and the effect is sustained after follow up 
also. It is not effective in reducing VLDL and increasing 
HDL.  
probable mode of action of the drug 
Medovikara is a condition of increased Medodhatu 
associated with increased Kaphadosha and deranged Kleda 
in body. It is characterized by excessive accumulation and 
deposition of Medodhatu obstructing the normal function 
of Medovahasrotas. Aetiological factors of Medovikara 
includes excessive involvement of food having the qualities 
like Snigdha, Guru, Picchila, Sheeta and Madhura rasa, lack 
of activity, lack of exercise, habituate day sleep etc. It will 
lead to increase state of Kapha, Meda and Kleda in the 
body. Medodhathu formed in the body is in Apakva form 
due to Dhathvagnimaandya. So the treatment should aim 
at the correction of Agni and Lekhana of the accumulated 
Medas.  
In Medovikaras, due to Medodhatvagnimandhya- 
Ashthayimedas increases in quantity and enters the 
circulation. Due to its Pichilaguna (sliminess), it gets 
lodged in susceptible Srotases (physiological channels) 
causing Margavarodha (obstruction). So the drugs should 
have Ruksha (rough), Chedana (breaking), Snehameda-
kleda visoshana property (reduces) to produce 
Srothovisodana (purification of channels). Both Kshara and 
Hingu is mentioned under Chedana group of drugs[12,13]. 
Both the drugs have Katurasa (pungent taste), Ushna-
veerya (hot in potency), Sukshma and Teekshna 
properties.[13,14] Hingu is with Katuvipakaalso[14]. The drug 
Eranda is with Katu, Tikta rasa and Ushnaveerya[15]. So 
there may be an effect of this combination in reducing fat 
molecules in the body. So it may act at Dhatwagni level, 
correcting Medodhathwagnimandya and helps in formation 
of proper Medodhathu in the body.  
The probable mode of action of a substance can be 
evaluated through its Rasapanchaka and Panchabhautika 
constitution. In the study, both the drugs i.e., Eranda-
pathrakshara and Hingu are having Katurasa, Katuvipaka 
which are of Vayu, Akasa and Agnimahabhoota 
predominance. These are opposite to Gunas of Prithvi and 
Jala. Hence they will reduce Bhujaladhikamedas. 
Ushnaveerya of both drugs stimulates Jatharagni which in 
turn stimulates Medodhathwagni and ultimately reduces 
over production of Medas. Apart from that these drugs are 
also Laghu and Teekshnagunas which help in Lekhana 
karma. Sharngadhara included Kshara in Chedana group of 
drugs[16]. So it may scratch out (Unmoolayathi) the 
adherent Kapha and other Doshas from their places due to 
its Ushna, Laghu and Theekshna properties.  
It is mentioned that in Kaphaja diseases, drug 
should be used in an order of Katu, Tiktha and Kashaya 
rasa[17]. As Medodhatu is having Snigdha (unctuousness), 
Guru (heaviness) and Pichilaguna (sliminess) it is 
moreover similar to Kaphadosha and Medovridhi can be 
considered as a Kaphajavyadhi. Both the drugs i.e. Eranda-
pathrakshara and Hingu are having Katurasa, so they have 
a predominant role in curing Kaphaja disease. The 
Katurasa, which is used first, will subside the Pichilathwa 
(sliminess) and Guruthwa (heaviness) of Kaphadosha 
resulting in alleviation of disorders related to Kaphadosha.  
 Thus it can be concluded that the study drugs 
Erandapathrakshara and Hingu is effective in reducing 
total cholesterol, LDL, Triglycerides and Non HDL-C.  
CONCLUSION 
The study drug is found to be effective in lowering 
total cholesterol, LDL, Non HDL-c and triglycerides but not 
effective in increasing HDL level and decreasing VLDL 
level. No adverse effects were observed during study, so 
the study drugs can be used safely for clinical practice.  
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